GSK plc (GLAXF)

GlaxoSmithKline, known as GSK, is one of the world’s largest pharmaceutical manufacturers — a company where the customers are healthcare providers, hospitals, and government medical systems, and the end users are patients who need its medicines to live longer or healthier lives. The company operates across three broad therapeutic areas: vaccines, respiratory medicines, and oncology treatments. Unlike consumer brands where customers choose between competitors on the shelf, GSK’s products are prescribed by doctors, approved by regulators, and covered by insurance — which means the true customer is often the healthcare system making reimbursement decisions, not the patient themselves. This creates a fundamentally different business model from consumer industries: pricing power is constrained by public health policy and government negotiation, and success depends on rigorous clinical evidence that a drug actually works better than alternatives.

GSK was created in 2000 when GlaxoWellcome and SmithKline Beecham merged, bringing together two of Britain’s oldest pharmaceutical houses. GlaxoWellcome traced back to Allen and Hanburys, founded in 1715 as an apothecary; SmithKline Beecham had roots in Philadelphia dating to the 18th century. The merged company inherited a portfolio of established medicines — antivirals, antibiotics, antidepressants — and a large research engine devoted to discovering new ones. For two decades, GSK was run as a traditional integrated pharma house, with blockbuster drugs like Avandia (diabetes), Azelastine (allergy), and Advair (respiratory) providing most of the profit. Like many large pharmaceutical firms in the 2010s, GSK struggled as patents expired on older drugs and the pipeline failed to deliver consistent replacements. In 2017, the company underwent a deliberate transformation: it spun off its consumer health business (toothpaste, cold remedies, and over-the-counter pain relievers, sold to private-equity buyers) and refocused entirely on prescription pharmaceuticals and vaccines. The newly slimmed GSK committed to investing heavily in what it called “sharpened focus” — vaccines, oncology, and immune-mediated diseases like respiratory conditions.

The restructuring was not merely symbolic. GSK built a separate biologics manufacturing footprint optimized for complex medicines like monoclonal antibodies and recombinant proteins. It acquired specialty biotech firms to gain expertise in niche disease areas — most notably, Haleon was spun out in 2022 as the consumer health company, leaving GSK to concentrate on prescription and vaccine segments. The company now employs tens of thousands of scientists, physicians, and manufacturing staff across labs and plants in the United Kingdom, the United States, Belgium, Germany, and Asia. This structure reflects a hard truth about modern pharmaceuticals: developing a single drug can take 10–15 years, cost several billion dollars, and fail nine times for every one that succeeds. Only companies large enough to absorb those losses and patient enough to wait can compete consistently.

GSK’s revenue comes from three main sources, each with different economics. Vaccines, including the shingles vaccine Shingrix and routine childhood vaccines, are increasingly important — they are made at scale once proven safe and effective, and governments and public-health systems order them in large quantities, providing predictable recurring revenue. Respiratory medicines, including asthma and COPD treatments, represent a large installed base of chronic patients who need refills regularly, generating stable cash flow. Oncology is the highest-risk, highest-reward segment: cancer drugs command premium prices because they extend life, often for patients with no better alternatives, but each one takes years to develop and succeeds or fails on narrow margins of clinical superiority over competitors.

The pharmaceutical business model is unlike most others because it is built on patents and regulatory moats rather than manufacturing scale or brand preference. Once a drug is approved by regulators such as the FDA, it has exclusive rights to that formula for a set period — typically 20 years from the filing date, sometimes extended through pediatric exclusivity or other mechanisms. During that window, competitors cannot copy the drug, so GSK has true pricing power and can charge what the market will bear. But once the patent expires, generic manufacturers can produce identical copies at a fraction of the original price, and sales often collapse overnight. This creates enormous pressure on GSK to maintain a pipeline of new drugs coming onto the market before old ones lose exclusivity. A company that loses blockbusters faster than it replaces them will see revenues fall sharply, which is exactly what happened to many traditional pharma firms in the 2000s and 2010s.

GSK’s research productivity has been uneven. The company spent tens of billions on research over the past decade but saw some expected failures: drugs that showed promise in animal studies or early human trials failed in late-stage testing, or succeeded but were not meaningfully better than existing alternatives. Success in pharmaceuticals is not rewarded with slight improvements — regulators expect new drugs to be genuinely better in some way: more effective, safer, or easier to use than what exists. The highest prices go to drugs that address unmet needs, where no good treatment exists yet, or where the therapy extends survival in advanced disease. GSK has had wins in this space — oncology medicines such as Blenrep and Jemperli have found markets in cancers where few alternatives exist — but the pipeline remains a source of investor concern because the company is dependent on drugs approved in the next few years to offset patents expiring on older medicines.

Profitability in pharma is high relative to many industries, but it is volatile. A single drug can account for 10–20% of revenue while it is on patent, and its loss can be catastrophic. GSK’s adjusted operating margins are typically in the 30–40% range, but reported margins are compressed by research spending and the amortization of acquired drug portfolios. This is where the scale of a company like GSK matters: it can afford to spend 15–20% of revenue on research because its established product base is big enough to fund that investment. A smaller competitor cannot.

GSK faces structural challenges common to all pharmaceutical firms. Governments and insurers are increasingly aggressive about negotiating prices, particularly for chronic diseases where cheaper alternatives exist. The United States implemented a historic change in 2023 when Medicare was authorized to negotiate prices directly with manufacturers for the first time — a shift that will lower prices on some of GSK’s biggest medicines in the American market, reducing global revenue. Simultaneously, development timelines remain long, success rates remain low, and the cost of bringing a drug to market keeps rising. Regulatory expectations for clinical evidence are stricter than they were a decade ago, which is good for patient safety but bad for speed and expense.

For someone considering GSK as an investment, the key question is whether the research pipeline is competitive. The 10-K filing (SEC CIK 0001131399) lists drugs in development and the stages they are at — early trial, late trial, or awaiting approval — and investors watch carefully to see whether GSK has candidates that could become blockbusters. The quarterly earnings calls discuss safety recalls, patent expirations, and the state of negotiations with governments and insurers. Metrics that matter include the growth rate of vaccines revenue (a relatively stable segment), the performance of major oncology launches, and the percentage of revenue coming from drugs approved in the past five years (higher is better, because older drugs are losing patent protection). The competitive landscape includes other global manufacturers like Roche, Merck, Pfizer, and smaller biotech specialists; GSK must compete on clinical superiority and the cost-effectiveness of its medicines relative to alternatives. Like any publicly traded company, GSK’s shares are priced by the market, and nothing here is investment advice — only a portrait of how the business works and where its dependencies lie.